Dr. Christopher Boniquit, M.D. Urology Medicare: Accepting Medicare Assignments Practice Location: 396 Remington Blvd, 310, Bolingbrook, IL 60440 Phone: 630-226-1436 |
Vibha Sabharwal, M.D. Urology Medicare: Accepting Medicare Assignments Practice Location: 396 Remington Blvd, Suite 310, Bolingbrook, IL 60440 Phone: 630-226-1436 Fax: 630-226-6938 |
News Archive
Democratic Sens. Jay Rockefeller (W.Va.) and Charles Schumer (N.Y.) in a letter to HHS Secretary Mike Leavitt wrote that there "have been several misleading - and possibly incorrect - reports from the [Bush] administration regarding actions on physician claims filed beginning July 1," The Hill reports (Young, The Hill, 6/30).
Scientists at the University of Granada have confirmed that injecting a local anesthetic or botulinum toxin (botox) into certain points named "trigger points" of the pericraneal and neck muscles reduce migraine frequency among migraine sufferers. University of Granada researchers have identified the location of these trigger points -which activation results in migraine- and their relationship with the duration and severity of this condition.
Scientists in Canada and the United States have used three-dimensional imaging techniques to settle a long-standing debate about how DNA and structural proteins are packaged into chromatin fibres. The researchers, whose findings are published in EMBO reports, reveal that the mouse genome consists of 10-nm chromatin fibres but did not find evidence for the wider 30-nm fibres that were previously thought to be important components of the DNA architecture.
ArthroCare Corp., a leader in developing state-of-the-art, minimally invasive surgical products, announced today the publication of an important clinical trial demonstrating that patients treated with ArthroCare's Plasma Disc Decompression (PDD) products experienced reduced pain and better quality of life scores compared to patients treated with the current standard care, epidural steroid injections.
Spinifex Pharmaceuticals, an Australian pain drug development company, today announces positive headline results from the Phase 2 clinical trial of its lead product, EMA401, in postherpetic neuralgia (PHN), a painful condition that develops in some patients following herpes zoster (shingles) and where existing therapy does not relieve pain in all individuals.
› Verified 3 days ago